DocDollars

Revance Therapeutics, Inc.

TN · United States · Reporting entity ID 100001448152

Total reported 2019–2025
$5.99M
#648 of 2,960 reporting companies — 0% of all reported industry payments
$5.99M in general payments across 45,148 records.

How it breaks down

General payments $5,990,627

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Revance Therapeutics, Inc. reported $5.99M to US doctors and teaching hospitals from 2019 to 2025, ranking #648 of 2,960 reporting companies. All of it was general payments such as consulting, speaking, food and travel. 45,148 general payment records were filed.

Common questions about Revance Therapeutics, Inc.

How much has Revance Therapeutics, Inc. paid US doctors?

Revance Therapeutics, Inc. reported $5,990,627 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $5,990,627 in general payments.

How does Revance Therapeutics, Inc. rank among drug and device companies?

It ranks #648 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Revance Therapeutics, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.